Abivax SA (ABVX) vs Grifols S.A. (GRFS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Grifols S.A. (GRFS) has outperformed Abivax SA (ABVX) over the past year, losing 3.0% versus a loss of 38.5%. Abivax SA is the larger company by market cap ($6.41 billion vs $5.55 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVX | GRFS |
|---|---|---|
| Share price | $73.20 | $8.15 |
| Market cap | $6.41B | $5.55B |
| 1-day change | -9.24% | -0.61% |
| YTD return | -45.72% | -12.83% |
| 1-year return | -38.55% | -2.98% |
| 5-year return | — | -25.30% |
| P/E ratio (TTM) | — | 9.82 |
| Forward P/E | — | 6.55 |
| EPS (TTM) | $-6.08 | $0.83 |
| Dividend yield | 0.00% | 1.30% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $148.83 | $9.77 |
| 52-week low | $62.70 | $6.96 |
| Distance from 52-week high | -50.82% | -16.58% |
| Analyst consensus | none | buy |
| Avg. price target upside | +123.47% | +27.24% |
| Average volume | 1.35M | 628.64K |
| Shares outstanding | 87.54M | 258.22M |
| Employees | 98 | 25,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRFS has outperformed ABVX by 35.6 percentage points over the past year.
- Grifols S.A. offers a meaningfully higher dividend yield (1.30% vs 0.00%).
About Abivax SA
ABVX stock →ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees
About Grifols S.A.
GRFS stock →Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Health Care · Biotechnology: Pharmaceutical Preparations · 25,000 employees
ABVX vs GRFS FAQ
Which is bigger, Abivax SA or Grifols S.A.?
Abivax SA (ABVX) is larger, with a market capitalization of $6.41B compared with $5.55B for Grifols S.A. (GRFS).
Which stock has performed better over the past year, ABVX or GRFS?
GRFS returned -2.98% over the past 12 months, compared with -38.55% for ABVX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Abivax SA or Grifols S.A.?
Grifols S.A. pays a dividend yielding 1.30%, while Abivax SA does not currently pay a regular dividend.
Are Abivax SA and Grifols S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.